The International Therapeutic Psilocybin Rescheduling Initiative (ITPRI) has launched today to push for the rescheduling of psilocybin across the globe.
Results from a new study have demonstrated that 10mg or 25mg doses of psilocybin have no long- or short-term detrimental effects in healthy individuals.
Braxia Scientific has dosed the first patients in its multi-dose psilocybin clinical trial exploring the compound’s efficacy for treatment-resistant depression (TRD).
Cybin is to meet with the UK’s Medical and Healthcare Products Regulatory Agency (MHRA) to discuss its lead psychedelic candidate CYB003 as a treatment for Major...
MYND has received the funding that will go towards its research and development into the effects of psilocybin for treating brain and central nervous system diseases.
The clinical trial is aiming to understand how psilocybin alters brain function in order to improve treatment options for mental illness.
The US Food and Drug Administration (FDA) has given authorisation for a Phase II clinical trial to evaluate psychedelic-assisted psychotherapy for frontline clinicians who are experiencing...
As regulation surrounding psychedelics develops across the globe, Numinus Wellness has created a toxicity and potency screening test that will facilitate safety and efficacy testing of...
A group of experts gathered to discuss microdosing, and separate the fact from the fiction on the safety and efficacy of the practice.
Diamond Therapeutics has now dosed the first cohort of its Phase I low-dose psilocybin clinical trial.